TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05394818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
Study: NCT06643195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ImmediateAllogeneic Hematopoietic Stem Cell Transplantation
Description: patients proceeded to allogeneic HSCT as soon as possible. Patients were allowed to receive low-dose chemotherapy that is not intended for the purpose of achieving a second remission.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retreatment
Description: Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
Study: NCT05669339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
Study: NCT05874544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Antibiotics for H. pylori eradication
Study: NCT05513716

Intervention type: OTHER
Intervention: Retrospective tissue sample analysis
Description: Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
Study: NCT05144763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePOCT+
Description: ePOCT+ is an electronic clinical decision support algorithm
Study: NCT05867667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehab
Description: Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
Study: NCT04066348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: To treat blast or noise induced tinnitus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT04948749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent implantation
Description: The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggressive medical treatment
Description: Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk factor management
Description: Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk factor management
Description: Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
Study: NCT05300711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery
Description: Colorectal surgery as indicated by attending surgeon.
Study: NCT06140056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation
Description: Mechanical ventilation mode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volumen controlled mechanical ventilation
Description: Mechanical ventilation mode
Study: NCT06240169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with MTA in AGEI
Description: DPC using MTA in 18-40 years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with BD in AGEI
Description: DPC using BD in 18-40 years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with MTA in AGEII
Description: DPC using MTA in 41-60Years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPC with BD in AGEII
Description: DPC using BD in 41-60Years
Study: NCT06370689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes
Study: NCT04369547

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
Study: NCT06370689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes
Study: NCT04369547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
Study: NCT06370689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation
Description: Preoxygenation of volunteers over 3 minutes
Study: NCT04369547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast 250mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo capsule matched to roflumilast capsule
Study: NCT03897049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans Women Connected
Description: The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health App
Description: The control group will download a mobile app that addresses COVID and provides COVID resources.
Study: NCT05463289

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point of Care Autonomous AI diabetic retinopathy exam
Description: Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
Study: NCT06032195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: heart will preserved in and will be treated with Custodiol-N solution
Study: NCT04985747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polished palatal surface
Description: Polishing of the anterior palatal surface using a polisher

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polished palatal surface
Description: Polishing of the anterior palatal surface using a polisher

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roughened palatal surface
Description: Roughening of the anterior palatal surface using a sandblaster

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roughened palatal surface
Description: Roughening of the anterior palatal surface using a sandblaster

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opened palatal surface
Description: Opening of the anterior palatal surface using acrylic bur

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opened palatal surface
Description: Opening of the anterior palatal surface using acrylic bur
Study: NCT06032195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: heart will preserved in and will be treated with Custodiol solution
Study: NCT06011525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard cold cap
Description: Standard cold-cap applied throughout anthracycline- and taxane-based chemotherapy treatment.~This device will be supplemented by a compressive bandage in order to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the efficacy of the device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp-cooling technique
Description: Scalp-cooling technique applied throughout anthracycline- and taxane-based chemotherapy treatment
Study: NCT06538727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation Treatment - Scapular Release
Description: First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
Study: NCT05131685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction
Description: closed reduction under conscious sedation followed by casting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: immobilization in cast without reduction
Study: NCT05957952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor control exercise with dynamic taping
Description: Subjects will learn how to control their scapula during motor control exercise with application of dynamic tape

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Motor control exercise
Description: Subjects will learn how to control their scapula during motor control exercise without taping
Study: NCT04623099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
Study: NCT06461962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Peer-facilitated referral to a local primary care provider to follow-up their screening results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth-Cardiology
Description: Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer~Referral for a locally performed testing including echocardiogram~Transitional care management facilitated by a remote nurse care manager and the peer
Study: NCT06294639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: esketamine will be given intravenously
Study: NCT05804526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC88
Description: 1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
Study: NCT05478720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-10 mg/kg per dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous dose of saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-diazo-5-oxo-L-norleucine (DON)
Description: Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
Study: NCT04781530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)
Description: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
Study: NCT04789668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06047977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
Description: Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)
Study: NCT06544733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4182
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match BVY
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Match GS1720/GS-4182 FDC
Description: Tablets administered orally without regard to food
Study: NCT05939830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stained region Lymph Node Biopsy (SrLNB)
Description: Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional lymph node radiotherapy (RNI) including the axilla
Description: RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
Study: NCT05239546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
Study: NCT06479161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: 1.95 grams oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1.95 grams oral
Study: NCT06114784

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomics
Description: Clinical metagenomics is used to evaluate pathogens
Study: NCT05691478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scintography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scintography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scintography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scintography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scintography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT05296083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G3P-01
Description: G3P-01 is a food-grade pectic product derived from squash.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G3P-01
Description: G3P-01 is a food-grade pectic product derived from squash.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G3P-01
Description: G3P-01 is a food-grade pectic product derived from squash.
Study: NCT05691478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05296083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G3P-01
Description: G3P-01 is a food-grade pectic product derived from squash.
Study: NCT05622838

Intervention type: DIAGNOSTIC_TEST
Intervention: Alpha1 -Antitrypsin level
Description: measuring alpha1 -antitrypsin level in pregnant women

Intervention type: DIAGNOSTIC_TEST
Intervention: Alpha1 -Antitrypsin level
Description: measuring alpha1 -antitrypsin level in pregnant women

Intervention type: DIAGNOSTIC_TEST
Intervention: Alpha1 -Antitrypsin level
Description: measuring alpha1 -antitrypsin level in pregnant women